Supplemental Table II.
Patients characteristics from patients with HFREF and HFPEF.
| Variables | HFREF LVEFLVEF ≤ 40% | HFPEF LVEFLVEF > 40% |
|---|---|---|
| N | 368 | 114 |
| Age (years) | 69 ± 12 | 74 ± 10 |
| Gender (% male) | 66 | 50 |
| NYHA (%, II / III / IV) | 42/55/4 | 53/43/4 |
| BMI (kg/m2) | 26 ± 5 | 28 ± 6 |
| LVEF (%) | 26 ± 8 | 53 ± 8 |
| eGFR (mL/min/1.73m2) | 55 ± 20 | 53 ± 21 |
| Hb (g/dL) | 13.5 ± 1.9 | 12.6 ± 2.2 |
| BNP (pg/mL) (median; IQR) | 511 (232 – 1110) | 310 (152 – 605) |
| NT-proBNP (pg/mL) (median; IQR) | 3045 (1597 – 7278) | 1898 (839 – 3827) |
| Galectin-3 (ng/mL) (median; IQR) | 19.9 (14.8 – 25.7) | 20.2 (16.0 – 26.0) |
| Medical history (%) | ||
| Hypertension | 40 | 51 |
| Myocardial Infarction | 44 | 30 |
| Diabetes | 28 | 29 |
| Atrial Fibrillation | 42 | 54 |
| COPD | 27 | 31 |
| CVA | 11 | 10 |
| Medication (%) | ||
| ACE inhibitors | 77 | 58 |
| ARB | 10 | 16 |
| Beta-blocker | 72 | 60 |
| Diuretics | 96 | 95 |